https://scholars.lib.ntu.edu.tw/handle/123456789/568675
標題: | Prospect of individualized medicine in chronic hepatitis C therapy by pharmacogenomics | 作者: | Hwang Y. Su C. Chen D.-S. PEI-JER CHEN |
關鍵字: | Genetic polymorphism; HVC; Interferon; Pharmacogenomics | 公開日期: | 2006 | 出版社: | Bentham Science Publishers B.V. | 卷: | 4 | 期: | 2 | 起(迄)頁: | 157-167 | 來源出版物: | Current Pharmacogenomics | 摘要: | Interferon-α and ribavirin combination therapy has been the current choice for treating chronic hepatitis C (CHC) patients. The treatment takes 6 to 12 months but the overall sustained response rate is only around 50% and often brings significant adverse effects to some patients. The treatment outcome has been shown to be associated with various viral factors, such as viral loads before and during treatment and, most importantly, viral genotypes and quasispecies. Host factors that may affect drug response include age, gender, ethnicity, HLA alleles and stage of liver fibrosis. Recent studies have further indicated an association between patients' genotypes and their treatment efficacy. In this review article, we evaluate and summarize factors that may contribute to the treatment outcome of CHC. The content is divided into four categories: 1. viral factors: viral load, viral genotype and early viral response; 2. general host factors: gender, age, treatment period/ dosage and kinds of IFN; 3. host genetic polymorphisms, particularly single nucleotide polymorphism (SNP) association studies; and 4. gene expression profiles in hepatitis C liver tissues. In summary, recent advances in pharmacogenomics have demonstrated the potential applications of genetic polymorphisms and expression patterns in determining treatment responsiveness in chronic hepatitis C. By combining both human and viral genotypes and their expression, it becomes plausible to satisfactorily assess the clinical outcomes prior to interferon combination treatment for CHC patients. ?2006 Bentham Science Publishers Ltd. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84984550815&doi=10.2174%2f157016006776286882&partnerID=40&md5=836ac1a5ca7bc3180877a19260847d13 https://scholars.lib.ntu.edu.tw/handle/123456789/568675 |
ISSN: | 1570-1603 | DOI: | 10.2174/157016006776286882 | SDG/關鍵字: | alpha interferon; beta interferon; chemokine receptor CCR5; cytotoxic T lymphocyte antigen 4; gamma interferon; interleukin 10; Myxovirus resistance protein A; peginterferon; polypeptide; ribavirin; transforming growth factor beta1; transporter associated with antigen processing 1; tumor necrosis factor alpha; age distribution; allele; article; drug response; ethnology; gene expression profiling; genetic association; genotype; hepatitis C; host resistance; human; liver fibrosis; monotherapy; nonhuman; nucleotide sequence; pharmacogenomics; proteomics; sex difference; single nucleotide polymorphism; treatment outcome; unspecified side effect; virus load; Hepatitis C virus |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。